Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer

Published:2015-10 Issue:5 Volume:13 Page:441-446
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Petrioli Roberto,Roviello Giandomenico,Fiaschi Anna I.,Laera Letizia,Bianco Vincenzo,Ponchietti Roberto,Barbanti Gabriele,Francini Edoardo

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference37 articles.

1. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target;Chen;Lancet Oncol,2009

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

5. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients Who Cannot Receive Cytotoxic Chemotherapy;The Korean Journal of Urological Oncology;2020-08-31

2. Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?;Medicine;2019-06

3. Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone;Investigational New Drugs;2018-10-22

4. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial;Clinical Genitourinary Cancer;2018-04

5. Estramustine phosphate induces prostate cancer cell line PC3 apoptosis by down-regulating miR-31 levels;EUR REV MED PHARMACO;2018